文献速递炎症性肠病

炎症性肠病患者接受维得利珠单抗与抗肿瘤坏死因子治疗后术后手术部位感染风险:倾向性评分匹配分析

Risk of post-operative surgical site infections after vedolizumab vs anti-tumour necrosis factor therapy: a propensity score matching analysis in inflammatory bowel disease.
PubMed 文献 · Aliment Pharmacol Ther · 2018-06-07

基于Optum研究数据库,纳入2015年1月至2016年12月腹部手术前30天内接受维得利珠单抗或抗肿瘤坏死因子治疗的炎症性肠病患者,经1:1倾向性评分匹配后比较术后手术部位感染风险。匹配样本186例(维得利珠单抗94例,抗肿瘤坏死因子92例),术后手术部位感染率两组无显著差异(抗肿瘤坏死因子12.0% vs 维得利珠单抗14.9%,P=0.56)。多变量分析显示营养不良是发生手术部位感染的唯一危险因素(OR 3.1,95%CI 1.11-8.71)。

要点

  • 匹配后维得利珠单抗组与抗肿瘤坏死因子组术后手术部位感染率无显著差异(14.9% vs 12.0%,P=0.56)。
  • 营养不良是术后手术部位感染的唯一危险因素(OR 3.1,95%CI 1.11-8.71),与生物制剂类型无关。
  • 维得利珠单抗组更可能接受开放肠切除加造口手术。

核心结论

  • 在迄今最大规模的风险校正队列分析中,围手术期暴露于维得利珠单抗治疗与抗肿瘤坏死因子治疗相比,未与显著更高的手术部位感染风险相关。

研究设计与样本

  • 利用Optum研究数据库识别2015年1月至2016年12月期间腹部手术前30天内接受维得利珠单抗或抗肿瘤坏死因子治疗的炎症性肠病患者,以炎症性肠病相关腹部手术日期为索引日期。
  • 通过倾向性评分1:1匹配建立可比的维得利珠单抗暴露与抗肿瘤坏死因子暴露队列,匹配基于循证风险修正因素。
  • 倾向性匹配样本共186例接受术前生物制剂治疗的患者(维得利珠单抗94例,抗肿瘤坏死因子92例)。

主要发现

  • 维得利珠单抗组与抗肿瘤坏死因子组在年龄、性别、炎症性肠病类型、合并免疫调节剂暴露、慢性阿片类或皮质类固醇治疗、Charlson合并症指数及营养不良方面相似。
  • 维得利珠单抗组更可能接受开放肠切除加造口手术。
  • 倾向性评分匹配后,术后手术部位感染率两组无显著差异(抗肿瘤坏死因子12.0% vs 维得利珠单抗14.9%,P=0.56)。
  • 多变量分析显示营养不良是发生手术部位感染的唯一危险因素(OR 3.1,95%CI 1.11-8.71),与生物制剂暴露类型无关。

关键数值与推荐

  • 术后手术部位感染率:抗肿瘤坏死因子组12.0% vs 维得利珠单抗组14.9%,P=0.56,无显著差异。
  • 营养不良与手术部位感染风险的OR为3.1(95%CI 1.11-8.71),与生物制剂类型无关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Perioperative vedolizumab (VDZ) and anti-tumour necrosis factor (TNFi) therapies are implicated in causing post-operative complications in inflammatory bowel disease (IBD). AIM: To compare the risk of surgical site infections (SSIs) between VDZ- and TNFi-treated IBD patients in propensity-matched cohorts. METHODS: The Optum Research Database was used to identify IBD patients who received VDZ or TNFi within 30 days prior to abdominal surgery between January 2015 and December 2016. The date of IBD-related abdominal surgery was defined as the index date. SSIs were determined by ICD-9/10 and CPT codes related to superficial wound infections or deep organ space infections after surgery. Propensity score 1:1 matching established comparable cohorts based on VDZ or TNFi exposure before surgery based on evidence-based risk modifiers. RESULTS: The propensity-matched sample included 186 patients who received pre-operative biologic therapy (VDZ, n = 94; TNFi, n = 92). VDZ and TNFi cohorts were similar based on age, gender, IBD type, concomitant immunomodulator exposure, chronic opioid or corticosteroid therapy, Charlson Comorbidity Index and malnutrition. VDZ patients were more likely to undergo an open bowel resection with ostomy. After propensity score matching, there was no significant difference in post-operative SSIs (TNFi 12.0% vs VDZ 14.9%, P = 0.56). Multivariable analysis indicated that malnutrition was the sole risk factor for developing SSI (OR 3.1, 95% CI 1.11-8.71) regardless of the type of biologic exposure. CONCLUSION: In the largest, risk-adjusted cohort analysis to date, perioperative exposure to VDZ therapy was not associated with a significantly higher risk of developing an SSI compared to TNFi therapy.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Park KT, Sceats L, Dehghan M, et al. Risk of post-operative surgical site infections after vedolizumab vs anti-tumour necrosis factor therapy: a propensity score matching analysis in inflammatory bowel disease. Aliment Pharmacol Ther. 2018. PMID: 29876995. doi:10.1111/apt.14842

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。